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ABSTRACT
Hypoxia is a feature of the tumour microenvironment that promotes
invasiveness, resistance to chemotherapeutics and cell survival. Our
studies identify the transient receptor potential canonical-1 (TRPC1)
ion channel as a key component of responses to hypoxia in breast
cancer cells. This regulation includes control of specific epithelial
to mesenchymal transition (EMT) events and hypoxia-mediated
activation of signalling pathways such as activation of the EGFR,
STAT3 and the autophagy marker LC3B, through hypoxia-inducible
factor-1α (HIF1α)-dependent and -independent mechanisms.
TRPC1 regulated HIF1α levels in PTEN-deficient MDA-MB-468 and
HCC1569 breast cancer cell lines. This regulation arises from effects
on the constitutive translation of HIF1α under normoxic conditions via
an Akt-dependent pathway. In further support of the role of TRPC1 in
EMT, its expression is closely associated with EMT- and metastasis-
related genes in breast tumours, and is enhanced in basal B breast
cancer cell lines. TRPC1 expression is also significantly prognostic
for basal breast cancers, particularly those classified as lymph node
positive. The defined roles of TRPC1 identified here could be
therapeutically exploited for the control of oncogenic pathways in
breast cancer cells.
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INTRODUCTION
The microenvironment of breast tumours is dynamic and can be a
key factor in contributing to breast cancer progression (Bissell and
Hines, 2011). One essential feature of the breast tumour
microenvironment is hypoxia (Semenza, 2016). Hypoxia in breast
tumours is a trigger for angiogenesis and other processes important
in metastasis, and in the preparation of the metastatic niche
(Semenza, 2013). Hypoxia is also crucial for the promotion of breast
cancer cells to a more invasive phenotype via epithelial to
mesenchymal transition (EMT) (Cooke et al., 2012; Lester et al.,
2007).
EMT in breast cancer cells is associated with a remodelling of
cellular adhesion through the loss of epithelial markers such as
E-cadherin, increased levels of specific transcription factors such as
Snail, Zeb and Twist family proteins, and the expression of
mesenchymal markers such as the intermediate filament protein
vimentin (Tomaskovic-Crook et al., 2009; Ye andWeinberg, 2015).
EMT is also associated with the acquisition of resistance to many
antineoplastic agents and increased invasiveness (Ye andWeinberg,
2015). We recently identified the Ca2+ signal as a regulator of the
induction of the EMT marker vimentin by epidermal growth factor
(EGF) (Davis et al., 2013). Hence, components of Ca2+ signalling in
breast cancer cells may represent opportunities to selectively exploit
and control specific metastatic and resistance pathways associated
with EMT.
Ca2+-permeable ion channels represent important and selective
regulators of intracellular Ca2+ homeostasis and responses to
external stimuli, and are encoded by over 40 genes. Transient
receptor potential (TRP) ion channels (Wu et al., 2010) have clear
physiological and pathological roles, and often act as sensors of
changing environmental cues. TRPV1 is a heat-responsive ion
channel, TRPM8 senses cold, and TRPM2 is sensitive to oxidative
stress (Wu et al., 2010) and is fundamental in signalling cascades
responsible for acetaminophen (paracetamol)-induced liver damage
(Kheradpezhouh et al., 2014). TRPC5 is important in semaphorin
3A-induced neuronal growth cone collapse (Kaczmarek et al., 2012)
and fear-related behaviour (Riccio et al., 2009), and is also
associated with the acquisition of multidrug resistance in breast
cancer cells (Ma et al., 2012, 2014). TRPC1 was the first TRP ion
channel identified in mammals (Wu et al., 2010) and it is expressed
in a variety of cell types (Cheng et al., 2013; Nilius and Szallasi,
2014); however, a detailed understanding of its role(s) in many
contexts remains unclear and controversial. TRPC1 has also been
described as contributing to store-operated Ca2+ entry, often in
association with the canonical store-operated Ca2+ channel
component Orai1 and the Ca2+ store sensor STIM1 (Cheng et al.,
2013).
TRPC1 is associated with pathophysiological processes in
hypoxia in smooth muscle cells of the pulmonary system, being
important in pulmonary vascular remodelling associated with
chronic hypoxia (Malczyk et al., 2013) and hypoxia-induced
enhancement of vascular tone (Xia et al., 2014). Chronic hypoxia is
also an inducer of TRPC1 expression in pulmonary arterial smooth
muscle cells via hypoxia-inducible factor 1α (HIF1α) (Wang et al.,
2006). Despite the link between hypoxia and TRPC1 in the vascular
system, no studies have explored the role of TRPC1 in the response
to hypoxia in breast cancer cells. We have assessed the potential role
of TRPCs in hypoxia-induced EMT in breast cancer cells and show
that a specific remodelling of TRPC1 expression is a feature of
hypoxia-associated EMT in breast cancer cells via HIF1α. We also
define TRPC1 as a regulator of specific hypoxia-induced changes inReceived 22 August 2016; Accepted 23 May 2017
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EMT marker induction. Unexpectedly, this regulation is through
both HIF1α-dependent and -independent mechanisms and involves
the differential regulation of specific cellular signalling pathways.
RESULTS
TRPC1 expression is increased during hypoxia and is
required for hypoxic induction of Snail and Claudin-4
We assessed the mRNA expression pattern of TRPC family genes in
MDA-MB-468 breast cancer cells, with the exception of TRPC2 (a
pseudogene in humans; Yildirim and Birnbaumer, 2007), in both
hypoxic and normoxic conditions. TRPC4, -5, -6 and -7mRNAwas
not detectable in either hypoxic or normoxic samples (Fig. 1A).
While TRPC3 mRNA levels were not significantly changed upon
hypoxia, TRPC1 mRNA levels were significantly increased
(Fig. 1A,Bi). Hypoxia-induced TRPC1 upregulation was also
observed in MDA-MB-231 and HCC1569 breast cancer cells
(Fig. S1). TRPC1 mRNA upregulation in MDA-MB-468 cells was
specific to hypoxia, as TRPC1 mRNA levels were modestly
downregulated upon addition of EGF, another EMT inducer
(Fig. 1Bii). Hypoxia-induced upregulation of TRPC1 was
dependent on HIF1α, as siRNA-mediated silencing of HIF1A
(Fig. 1Ci) attenuated hypoxia-induced TRPC1mRNA upregulation
(Fig. 1Cii). Assessment of potential HIF binding sites in the
promoter region of TRPC1 identified binding motifs for HIF1α and
HIF1β (Fig. S2). However, only the silencing of HIF1A reduced
hypoxia-mediated induction of TRPC1 mRNA levels (Fig. 1Cii);
siRNA against HIF1B or HIF2A had no effect on the increase in
TRPC1 expression (Fig. S3). Analysis of the gene expression profile
of TRPC1 in human breast cancer cell lines, revealed a significant
upregulation of TRPC1 in Basal B cell lines (which exhibit
enhanced mesenchymal-like features; Blick et al., 2010; Neve et al.,
2006) compared with other subgroups (Fig. 1D).
To determine whether TRPC1 is involved in the induction of
hypoxia-induced EMT, we assessed the effect of its siRNA-
mediated silencing on EMT markers. Hypoxia (24 h) resulted in
significant upregulation of the mesenchymal markers vimentin,
Snail (also known as SNAI1), Twist (TWIST1) and N-cadherin
(CDH2), and downregulation of the epithelial marker claudin-4
(CLDN4) (Fig. 1F). Silencing of TRPC1 (Fig. 1E) under hypoxic
conditions significantly attenuated the induction of the EMT
transcription factor Snail and partially prevented the reduction of
the epithelial marker claudin-4 (24 h); however, induction of the
other EMT markers by hypoxia was independent of TRPC1
(Fig. 1F). TRPC1 is therefore the first identified ion channel
regulator of the EMT transcription factor Snail and epithelial marker
claudin-4. This regulation appears to be hypoxia specific as
silencing of TRPC1 did not have any significant effect on the
basal levels of Snail and claudin-4 in normoxia (Fig. S4). The
differential regulation of hypoxia-mediated events was further
explored through assessment of cellular signalling pathways
activated by hypoxia in breast cancer cells.
TRPC1 is a regulator of hypoxia-induced EGFR and STAT3
activation
EGFR and STAT3 signalling are two key hypoxia-associated
signalling pathways (Selvendiran et al., 2009; Pawlus et al., 2014;
Peng et al., 2006) that also have important roles in EMT induced by
hypoxia (Cui et al., 2016; Misra et al., 2012) and EGF (Lo et al.,
2007), although their potential regulation by TRPC1 is unknown.
We assessed EGFR at Y1173 (an important site of EGFR
autophosphorylation; Kondratov et al., 2010) and STAT3
phosphorylation at Y705 in MDA-MB-468 cells under hypoxic
conditions for 6, 24 and 48 h. Phosphorylation of EGFR was
significantly enhanced after 24 and 48 h of hypoxia, with no
significant concomitant change in total EGFR protein (Fig. 2A).
Likewise, total STAT3 protein levels were not altered by hypoxia,
but phosphorylation of STAT3 was significantly increased at 24 h
(Fig. 2A). Silencing of TRPC1 with siRNA significantly reduced
hypoxia-induced EGFR and STAT3 phosphorylation, with no change
in total EGFR or STAT3 levels, respectively (Fig. 2B,C). Given the
upregulation of TRPC1 with hypoxia but not EGF (Fig. 1B), the
selective role of TRPC1 in hypoxiawas explored by silencing TRPC1
and assessing EGFR and STAT3 phosphorylation induced by EGF.
TRPC1 silencing did not alter EGF-induced phosphorylation of
EGFR (Fig. 2D) or inhibit STAT3 phosphorylation (Fig. 2E); instead,
augmentation of STAT3 phosphorylation was evident (Fig. 2E).
These findings provide further evidence for the selectivity of TRPC1
in hypoxia and identify a role for TRPC1 in hypoxia-induced
transactivation of EGFR.
Regulation of non-stimulated and store-operated Ca2+-entry
pathways by TRPC1 after hypoxia
TRPC1 has been implicated in store-operated Ca2+ entry in some
cell types (Cheng et al., 2013). Under normoxic conditions in
MDA-MB-468 breast cancer cells, TRPC1 is a regulator of non-
stimulated (constitutive) Ca2+ influx but not of store-operated Ca2+
entry (Davis et al., 2012). To assess whether hypoxia alters the
nature of the contribution of TRPC1 to Ca2+ influx, we assessed the
effects of TRPC1 silencing on non-stimulated (constitutive) Ca2+
influx and store-operated Ca2+ entry after hypoxia (Fig. 3).
Silencing of TRPC1 had no effect on the cytosolic free Ca2+
([Ca2+]CYT) increases associated with store depletion induced by the
sarco/endoplasmic reticulum Ca2+ ATPase inhibitor cyclopiazonic
acid (CPA) (Fig. 3A,B, peak 1). However, TRPC1 silencing
significantly augmented store-operated Ca2+ influx (Fig. 3A,B,
peak 2) and reduced non-stimulated Ca2+ influx compared with the
non-targeting control (Fig. 3A,B). Hence, hypoxia (24 h) was not
associated with a change in the nature of the contribution of TRPC1
to basal Ca2+ influx or store-operated Ca2+ entry, as the effects were
identical to those seen with normoxia (Davis et al., 2012).
TRPC1 regulates HIF1α levels and Akt activation in MDA-MB-
468 breast cancer cells
As TRPC1 modified specific EMT markers and cellular signalling
cascades induced by hypoxia, we sought to determine whether
TRPC1 was involved in the early induction of the hypoxic
transcriptional regulator HIF1α. Pronounced accumulation of
HIF1α protein was evident at 6 h, and this early induction was
significantly inhibited by silencing ofTRPC1 (Fig. 4A and Fig. S6A).
We assessed whether this regulation was solely through the reduced
ability of cells to sense reduced O2 levels by silencing TRPC1 and
examining basal protein and mRNA levels of HIF1α under normoxic
conditions. Consistent with its status as a PTEN-deficient breast
cancer cell line (Li et al., 1997; Zundel et al., 2000), MDA-MB-468
breast cancer cells exhibited some basal expression of HIF1α protein,
which was almost completely abolished upon TRPC1 silencing
(Fig. 4B), and this effect was not mediated through a decrease in
HIF1A mRNA levels (Fig. 4C). Hence, the effect of TRPC1 on
HIF1α protein did not occur via transcriptional modulation but rather
via effects on HIF1α translational and/or degradation.
Hypoxia-induced HIF1α protein stabilisation is predominantly
via inhibition of proteasome-mediated degradation as a result of low
levels of O2 (Salceda and Caro, 1997). To assess if TRPC1
regulation of HIF1α protein was through this O2-dependent
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proteolysis mechanism, we treated TRPC1-silenced and control
cells with the proteasome inhibitor MG132 (Salceda and Caro,
1997). As expected, MG132 treatment increased HIF1α protein
levels (Fig. 4D) and siRNA-mediated silencing of TRPC1 reduced
theMG132-induced increases in HIF1α (Fig. 4D). TRPC1 does not,
therefore, regulate HIF1α via proteasome-mediated degradation.
Another possible intersection between HIF1α and TRPC1 could
be via Akt (AKT1). HIF1α translation is upregulated by Akt (Pore
et al., 2006), and Akt activity is enhanced in PTEN-deficient cells
(Cantley and Neel, 1999; deGraffenried et al., 2004; Soria et al.,
2002), which include MDA-MB-468 cells (Li et al., 1997). We
therefore assessed the effects of TRPC1 silencing on the constitutive
activation of Akt and the role of the Akt pathway on HIF1α levels in
MDA-MB-468 cells. These studies were performed under normoxic
conditions since we showed that TRPC1 could regulate HIF1α
levels in the absence of hypoxia (see Fig. 4B). TRPC1 silencing
significantly reduced basal Akt phosphorylation but not total levels
of Akt protein (Fig. 4E), whereas basal phosphorylation of both
Fig. 1. TRPC1 expression is upregulated by hypoxia via HIF1α and its silencing attenuates hypoxia-induced changes in Snail and claudin-4.
(A) Transcriptional profile of TRPC isoforms [relative mRNA (−ΔCT)] showed selective upregulation of TRPC1 with hypoxia (24 h) [▪ denotes a target below the
limit of detection (CT >35)]. (B) TRPC1 induction in MDA-MB-468 cells 24 h after hypoxia (i) or 50 ng/ml EGF (ii). *P<0.05, **P<0.01 compared with control
(unpaired t-test), n=3, mean±s.d. (C) siRNA-mediated silencing ofHIF1A relative to non-targeting control (NT) (i) and its effect on hypoxia-induced TRPC1mRNA
upregulation (24 h hypoxia, ii). *P<0.01 (one-way ANOVA, with Bonferroni’s multiple comparisons), n=3, mean±s.d. (D) TRPC1 assessment in gene expression
data of 50 breast cancer cell lines and 5 non-malignant breast cell lines, including three subtypes of luminal, basal A and basal B/mesenchymal. Data are from
Array Express (accession no. E-MTAB-181) (Heiser et al., 2012) and are normalised log2-transformed values; *P<0.001, **P<0.0001 (one-way ANOVA, with
Tukey’s multiple comparisons). (E) Confirmation of TRPC1 siRNA-mediated silencing. (F) Effect of TRPC1 silencing on hypoxia-mediated induction of EMT
markers in MD-MB-468 cells. *P<0.01 (one-way ANOVA, with Bonferroni’s multiple comparisons), ns, not significant; n=3, mean±s.d.
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Fig. 2. TRPC1 promotes hypoxia but not EGF-induced EGFR(Y1173) and STAT3(Y705) phosphorylation. (A) MDA-MB-468 breast cancer cells were serum
reduced (24 h) and exposed to hypoxia for 6, 24 and 48 h; representative immunoblot and densitometry analysis of total EGFR and STAT3 (normalised to β-actin)
and phosphorylated EGFR (Y1173) and STAT3 (Y705) (normalised to β-actin and total EGFR and STAT3). *P<0.01, **P<0.001 (two-way ANOVA, with
Bonferroni’s multiple comparisons); ns, not significant. (B) Representative immunoblot and densitometry analysis of the effect of TRPC1 silencing on total EGFR
protein and phosphorylation with hypoxia (24 h). *P<0.001 (one-way ANOVA, with Bonferroni’s multiple comparisons). (C) Representative immunoblot and
densitometry analysis of the effect of TRPC1 silencing on total STAT3 protein and phosphorylation with hypoxia (24 h). *P<0.01 (Bonferroni one-way ANOVA).
(D) Representative immunoblot and densitometry analysis of the effect of TRPC1 silencing on total EGFR protein and phosphorylated levels with EGF (20 min).
(E) Representative immunoblot and densitometry analysis of the effect of TRPC1 silencing on total STAT3 protein and phosphorylation with EGF (20 min).
*P<0.05 (Bonferroni one-way ANOVA). The same membrane was blotted for both STAT3 and EGFR (both total and phosphorylated), and therefore the
same β-actin loading controls are used for comparisons in B and C, and D and E, respectively. All densitometry data presented are the mean±s.d. of three
independent experiments and normalised to β-actin. Relative protein expression is defined as quantification of fraction of total protein band intensity after
normalisation to β-actin loading control.
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EGFR and STAT3 were unaffected in normoxia (Fig. 4E), unlike the
decrease seen with TRPC1 silencing and hypoxia-induced EGFR and
STAT3 phosphorylation (Fig. 2B,C). MK-2206 2HCl, an Akt-
selective inhibitor, concentration-dependently phenocopied the
suppression of basal HIF1α levels by TRPC1 silencing (Fig. 4F),
implicating Akt as the conduit between TRPC1 andHIF1α translation.
Similarly, in PTEN-null HCC1569 breast cancer cells (Chou et al.,
2009), TRPC1 silencing (Fig. 4Gi) significantly reduced both basal
Akt phosphorylation (Fig. 4Gii) and basal HIF1α expression
(Fig. 4Giii). To confirm this observation, we overexpressed TRPC1
using a commercially available TRPC1 plasmid (Fig. 4Hi) and
examined the levels of HIF1α and Akt phosphorylation (Fig. 4Hii).
The data show that TRPC1 overexpression is sufficient to induce
HIF1α and Akt phosphorylation, and this induction of HIFα is
inhibited by Akt inhibition (Fig. 4Hii). These results highlight the
important role of TRPC1 in the Akt–HIF1α pathway in PTEN-
deficient breast cancer cells, even under normoxic conditions.
HIF1A silencing attenuates hypoxia-mediated changes in
SNAI1 gene expression and non-stimulated Ca2+ influx
Since we showed that HIF1α is a TRPC1-sensitive protein in this
model, we assessed whether HIF1α is an intermediate between
TRPC1 and the induction of EMT markers and cellular signalling
cascades induced by hypoxia. To achieve this aim, we silenced
HIF1A and compared these effects with those observed upon
TRPC1 silencing. Some of the effects of TRPC1 silencing were
independent of HIF1α. Silencing ofHIF1A phenocopied the effects
of TRPC1 silencing on hypoxia-induced changes in the expression
of Snail but not claudin-4 (Fig. 5A). Despite the ability of HIF1α to
regulate TRPC1 expression (as shown in Fig. 1C), HIF1A silencing
had the opposite effect of TRPC1 silencing on hypoxia-mediated
changes in EGFR and STAT3 phosphorylation (Fig. 5B). Although
this result may be unexpected, it is not totally surprising given that
TRPC1 expression is not reduced to the same degree by silencing of
HIF1A compared with TRPC1. Furthermore, HIF1α as a hypoxic
transcriptional regulator, may influence other pathways that may
have opposing effects to those of TRPC1 on EGFR and STAT3
activity. However, these results do clearly define effects of TRPC1
that are independent of HIF1α, namely hypoxia-induced changes in
claudin-4 expression and EGFR and STAT3 phosphorylation. The
differential contribution of HIF1α to the effects of TRPC1 silencing
was also evident when assessing Ca2+ homeostatsis. HIF1A
silencing reduced constitutive Ca2+ influx in a similar manner to
that seen with silencing of TRPC1; however, HIF1A siRNA did not
promote store-operated Ca2+ entry, as was seen upon TRPC1 siRNA
treatment (Fig. 5C). Hence, some of the responses of breast cancer
cells to hypoxia are clearly influenced by TRPC1, but the
contribution of TRPC1 appears to involve both HIF1α-dependent
and -independent mechanisms.
TRPC1 modulates hypoxia-induced changes in the
autophagy marker LC3B via regulation of EGFR
In addition to EMT, one other event associated with hypoxia is
autophagy. Autophagy is a key hypoxia-induced survival mechanism
seen in some cancer cells (Hu et al., 2012), and is Ca2+ signalling
dependent (Cárdenas et al., 2010; Decuypere et al., 2013; Kondratskyi
et al., 2013; Parys et al., 2012). TRPC1 silencing significantly reduced
the protein levels of the hypoxia-induced autophagy marker LC3BII
(also known as MAP1LC3BII, where II indicates the lipidated form)
(Fig. 6A and Fig. S6B). Silencing of EGFR also significantly
attenuated hypoxia-induced elevation of LC3BII levels, whereas
silencing of either STAT3 orHIF1A had no significant effect (Fig. 6B).
These results suggest that hypoxia increases LC3BII levels via a
TRPC1 pathway that is dependent on EGFR phosphorylation but is
independent of TRPC1-mediated regulation of hypoxia-induced
changes in HIF1α levels or STAT3 activity.
TRPC1 is associated with breast cancermolecular subtypes
with mesenchymal features and poor prognosis in basal
breast cancers
Collectively, the results above implicate TRPC1 in some of the
pathways associated with hypoxia-induced EMT. We assessed
Fig. 3. TRPC1 silencing attenuates non-stimulated Ca2+ influx and augments store-operated Ca2+ entry after hypoxia in MDA-MB-468 breast cancer
cells. (A) Mean [Ca2+]CYT levels during assessment of non-stimulated Ca2+ influx (DMSO control) and store-operated Ca2+ entry (SOCE; 10 µM CPA) with or
without TRPC1 siRNA silencing after exposure to hypoxia (24 h). (B) Quantification of relative [Ca2+]CYT (mean±s.d., n=3) normalised to the maximum peak
height of the store-operated Ca2+ entry of the non-targeting siRNA control. For each group, the siTRPC1 is compared with its non-targeting (NT) control. *P<0.05,
**P<0.01 (unpaired t-test).
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Fig. 4. TRPC1 regulation of HIF1α translation and basal activation of Akt in MDA-MB-468 breast cancer cells in normoxia. (A) Representative immunoblot
(left) and quantitative analyses (right) of the effect of TRPC1 siRNA-mediated silencing on hypoxia-induced (6 h) increases in HIF1α protein compared with NT
siRNA in normoxia and hypoxia (n=3, mean±s.d., *P<0.05, one-way ANOVA, with Bonferroni’s multiple comparisons). (B) Immunoblot (left) and quantitative
analysis (right) of HIF1α protein levels in MDA-MB-468 cells with TRPC1 and NT siRNA both under normoxic conditions (n=3, mean±s.d., *P<0.001, unpaired
t-test). (C) Assessment of the effect of TRPC1 silencing on HIF1A mRNA levels in normoxia (n=3, mean±s.d., *P<0.05, unpaired t-test). (D) Effect of TRPC1
silencing on MG132 proteasome inhibitor-induced increases in HIF1α protein (n=3, mean±s.d., *P<0.001, two-way ANOVA, with Bonferroni’s multiple
comparisons). (E) Levels of total and phosphorylated levels of Akt, EGFR and STAT3 in the absence and presence of TRPC1 siRNA in normoxia
(n=3, mean±s.d., *P<0.001, unpaired t-test). (F) Representative immunoblot (left) and quantitative analysis (right) of HIF1α protein levels in MDA-MB-468 cells
treated with the Akt inhibitor MK-2206 2HCl for 24 h (n=3, mean±s.d., *P<0.01, **P<0.001, one-way ANOVA, with Bonferroni’s multiple comparisons).
(G) Confirmation of TRPC1 silencing (i), and representative immunoblot and quantitative analysis of the basal level of Akt phosphorylation (ii) and HIF1α protein
(iii) in HCC1569 cells with TRPC1 silencing (n=3, mean±s.d., *P<0.01, **P<0.0001 unpaired t-test). All densitometry data are presented as the mean of
three independent experiments. The uncropped full blots of Gii are shown in Fig. S5. Relative protein expression is defined as quantification of fraction of
total protein band intensity after normalisation to β-actin loading control. (H) TRPC1 plasmid increases TRPC1 levels compared with PCDNA3.1 control plasmid
(3.1) (i; n=3, mean±s.d., *P<0.05, unpaired t-test,). TRPC1 overexpression increases levels of Akt phosphorylation and HIF1α protein in MDA-MB-468 cells and
these increases are reduced by the Akt inhibitor MK2206 (1 µM) (ii; n=3, mean±s.d., *P<0.05, **P<0.001, one-way ANOVA, with Bonferroni’s multiple
comparisons).
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whether such an association was also present in clinical breast
cancers given that some breast cancer subtypes are more enriched in
EMT markers than others. Our assessment of PAM50 breast cancer
molecular subtypes (Harrell et al., 2012), showed that the claudin-
low (C-Low) subtype (predominantly associated with EMT and
stem cell characteristics; Hennessy et al., 2009), had the highest
levels of TRPC1 expression, with significantly higher levels than
basal, HER2, luminal A and luminal B breast cancers [Fig. 7A,
expression data from The University of North Carolina (UNC)
(Harrell et al., 2012); see Materials and methods]. Consistent with
this result, assessment of the recently defined triple-negative breast
cancer (TNBC) subtypes identified the highest levels of TRPC1 in
Fig. 5. Assessment of the involvement of HIF1α in hypoxic events regulated by TRPC1. (A) Effect of HIF1A siRNA-mediated silencing on the levels of
hypoxia (24 h)-mediated upregulation of the mesenchymal marker SNAI1, and hypoxia-mediated downregulation of the epithelial marker Claudin-4 (24 h
hypoxia) (n=3, mean±s.d., *P<0.05, one-way ANOVA, with Bonferroni’s multiple comparisons). (B) Representative immunoblot (left) and quantitative analyses
(right) of the effect of HIF1A silencing on the levels of total and phosphorylated EGFR(Y1173) and STAT3(Y705) with 24 h hypoxia. All densitometry data are
presented as the mean±s.d. of three independent experiments (*P<0.01, one-way ANOVA, with Bonferroni’s multiple comparisons). (C) Mean [Ca2+]CYT levels
during assessment of non-stimulated Ca2+ influx (DMSO control) and store-operated Ca2+ entry (SOCE; 10 µM CPA) with or without HIF1A silencing after
exposure to hypoxia (24 h) (left), quantification of relative [Ca2+]CYT normalised to the maximum peak height of the store-operated Ca2+ entry of the non-targeting
siRNA control (right). For each group, the siHIF1α was compared with its non-targeting control. Values are mean±s.d., n=3; *P<0.05, unpaired t-test. Relative
protein expression is defined as quantification of the fraction of total protein band intensity after normalisation to β-actin loading control.
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the mesenchymal (MES) subtype, with significantly greater levels
than basal-like immune-activated (BLIA) and basal-like immune-
suppressed (BLIS) subtypes (Fig. 7B). High levels of TRPC1 are
associated with a significantly poorer prognosis in basal breast
cancers (Fig. 7C), particularly in basal breast cancers with positive
lymph node involvement [Fig. 7D; data sourced from Kaplan–
Meier (KM) plotter; Györffy et al., 2010]. To provide greater insight
into those breast cancers with high levels of TRPC1 expression, the
top 100 genes most positively (Table S1) and negatively (Table S2)
associated with TRPC1 in breast cancers were assessed by gene
ontology. Genes positively associated with TRPC1 were
significantly enriched for pathways and processes associated with
Fig. 6. Regulation of hypoxia-mediated induction of the autophagy marker LC3BII by TRPC1 and EGFR. (A) Assessment of the effect of TRPC1 silencing
on hypoxia (48 h)-mediated upregulation of LC3BII protein. Representative immunoblot (left) and quantitative analyses (right) of the LC3BII band as the
active autophagosome membrane-bound form. (B) Representative immunoblot (left) and quantitative analyses (right) of LC3BII levels with siRNA-mediated
silencing of HIF1A, EGFR and STAT3. All densitometry data are presented as the mean of three independent experiments (n=3, mean±s.d., *P<0.05, **P<0.01,
one-way ANOVA, with Bonferroni’s multiple comparisons). Relative protein expression is defined as quantification of fraction of total protein band intensity after
normalisation to β-actin loading control. (C) Schematic representation of proposed hypoxia-associated events regulated by TRPC1. TRPC1 regulates HIF-1α
protein levels via an Akt-dependent pathway. TRPC1 promotes EMT through upregulation of hypoxia-induced SNAI1mRNA expression via a HIF-1α-dependent
mechanism and downregulation of CLDN4. TRPC1 regulates activation of hypoxia-induced STAT3 and EGFR phosphorylation and hypoxia-induced LC3BII
levels via effects on EGFR.
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the mesenchymal phenotype such as those related towound healing,
migration, adhesion and development (Table 1 and Fig. S7). Indeed,
these processes are shown to be a consequence of EMT
(Tomaskovic-Crook et al., 2009), and the relationship between the
positively associated genes with TRPC1 and these processes further
supports the role of TRPC1 in EMT. In contrast, negatively
associated genes were associated with features often reduced as a
consequence of EMT, such as chromatin assembly, nucleosome
organization and M phase (Table 1 and Fig. S8). This analysis of
breast cancer subtypes provides further evidence for an association
between TRPC1 and some aspects of EMT.
DISCUSSION
As a primary tumour develops, the associated hypoxic environment
initiates events such as the induction of a more invasive phenotype
through EMT (Azimi and Monteith, 2016; Lester et al., 2007) and
cell survival via autophagy (Hu et al., 2012). The studies presented
here provide evidence for TRPC1 as a critical regulator of processes
induced by hypoxia via HIF1α-dependent and -independent
mechanisms. Our studies have also defined a role for TRPC1 in
the control of HIF1α expression under normoxic conditions in
PTEN-deficient breast cancer cells through an Akt-dependent
mechanism.
Initial evidence for a selective role of TRPC1 in hypoxia was the
upregulation of TRPC1 with hypoxia-induced EMT but not EGF-
induced EMT. Increases in TRPC1 channel expression were
sensitive to the silencing of a master regulator of hypoxia
responses, HIF1A (Weidemann and Johnson, 2008), consistent
with the prediction of TRPC1 as a HIF1α target gene (Ortiz-
Barahona et al., 2010). Cellular signalling can selectively control
different pathways to EMT induction (Kondratov et al., 2010) and
the subsequent array of events that include increased migration,
resistance to therapeutic agents and the remodelling of cellular
adhesion (Tomaskovic-Crook et al., 2009; Ye andWeinberg, 2015).
Our studies provide evidence for TRPC1 as a regulator of hypoxia-
mediated EMT pathways associated with changes in claudin-4 and
Snail. The observation that TRPC1 is highest in the claudin-low
(PAM50) and MES (TNBC) molecular subtypes, provides
compelling evidence for an association between TRPC1 and
aspects on the EMT pathway, and is consistent with its increased
expression in the basal B cell line subgroups, which show
enhanced mesenchymal-like features (Neve et al., 2006). The
relationship between genes positively correlated with TRPC1 and
pathways remodelled in EMT (e.g. wound healing, migration,
development, adhesion; Tomaskovic-Crook et al., 2009), further
support the placement of TRPC1 as an ion channel regulator of
aspects of EMT and therefore potentially metastasis (Semenza,
2013) and/or therapeutic resistance (Fischer et al., 2015). Indeed,
we found that elevated TRPC1 levels were associated with poor
survival in basal breast cancers, particularly those with lymph
node involvement.
TRPC1 is not a master regulator of all changes associated with
EMT induced by hypoxia since some EMT markers were
insensitive to TRPC1 silencing. As TRPC1 regulates hypoxia-
mediated changes in EMT markers via HIF1α-dependent and
-independent mechanisms (Fig. 6C), our work also reflects the
specificity of different signals in inducing EMT. The role of TRPC1
in hypoxia-mediated EMT is analogous to the role of the ion
channel TRPM7 in the control of EGF-induced protein expression
of the EMT marker vimentin, but not Twist and N-cadherin (Davis
Fig. 7. TRPC1 expression is
enriched in mesenchymal subtypes
of breast cancer and stratifies the
survival of basal patients with
metastatic relapse. (A) Expression of
TRPC1, log2 transformed, across the
five intrinsic subtypes of breast cancer,
including the basal and normal-like
derived claudin-low (C-Low).
(B) Expression of TRPC1, log2
transformed, across the four subtypes
of triple-negative breast cancer.
Expression data sourced from UNC
(Harrell et al., 2012). Statistical
significance for A and B was obtained
via a one-way ANOVA with multiple
comparisons corrected via Tukey test.
***P<0.001, ****P<0.0001; ns, not
significant. (C,D), Kaplan–Meier
curves for the stratification of patient
relapse-free survival by TRPC1
expression level in all basal tumours
and those that are lymph node-positive
(N+). Patient numbers in the high or
low expression groups are indicated in
brackets, log rankP-values and hazard
ratios (HRs) are displayed below each
graph; 95% confidence intervals in
brackets. Patient survival outcome
data sourced from KM-Plotter (see
Materials and methods for details).
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et al., 2013). Hence, TRPC1 and other ion channels such as
TRPM7, are involved in very specific aspects of EMT remodelling
and may therefore function as fine-tuners of EMT induction. They
therefore represent opportunities to therapeutically target specific
aspects of the mesenchymal phenotype in breast cancer.
TRPC1 silencing inhibited hypoxia- but not EGF-mediated
stimulation of EGFR(Y1172) and STAT3(Y705) phosphorylation.
Specific regulation by TRPC1 of hypoxia but not EGF responses,
indicated that this channel is not just a simple regulator of
Ca2+-dependent housekeeping functions required for activation of
the EGFR and STAT3 signalling pathways. Instead, TRPC1 is a
specific regulator of processes associated with the transactivation of
EGFR during hypoxia, which occurs through a HIF1α-independent
mechanism.We also demonstrated that TRPC1-mediated regulation
of EGFR activity during hypoxia is manifest as effects on the
autophagy marker LC3B (Fig. 6). In A549 lung carcinoma cells,
TRPC1 silencing inhibits EGF-induced phosphoryation of EGFR at
a different phosphorylation site (Y1068) (Tajeddine and Gailly,
2012), suggesting that TRPC1 selectively regulates signalling
cascades through differential control of autophosphorylation sites
(Nyati et al., 2006) and/or cell-type-specific roles for TRPC1 in
EGFR signalling. Cell-type-specific roles for TRPC1 are also
reflected in the regulation of store-operated Ca2+ entry (Cheng et al.,
2013; Davis et al., 2012). Indeed, in A549 but not MDA-MB-468
cells, TRPC1 is a regulator of store-operated Ca2+ entry (Davis et al.,
2012; Tajeddine and Gailly, 2012). This highly context-dependent
role for TRPC1 in store-operated Ca2+ entry may explain the major
differences in phenotypes between Trpc1- and Orai1 (the classical
store-operated Ca2+ entry component)-knockout mice: Orai1-null
mice are associated with much more severe effects than Trpc1-
knockout mice (Liu et al., 2007), including compromised immunity
(Kim et al., 2011) and defects in osteoblast function (Robinson
et al., 2012). TRPC1 is not the only Ca2+-influx pathway where its
contribution is dependent upon the cell identity because silencing of
ORAI3 inhibits store-operated Ca2+ entry in oestrogen-receptor-
positive but not oestrogen-negative breast cancer cell lines (Motiani
et al., 2010).
TRPC1 is not responsible for store-operated Ca2+ entry in either
normoxia (Davis et al., 2012) or after hypoxia in MDA-MB-468
breast cancer cells; indeed, TRPC1 silencing produces a modest
increase in store-operated Ca2+ entry. However, our studies do show
that TRPC1 is a major regulator of non-stimulated Ca2+ influx after
hypoxia. The contribution of TRPC1 on basal [Ca2+]CYT is
associated with the pathogenesis of chronic hypoxia-induced
pulmonary hypertension (Wang et al., 2015) and in cardiac
myocytes, where the contribution of TRPC1 with TRPC4 to basal
Ca2+ influx plays an important role in the development of cardiac
hypertrophy (Camacho Londoño et al., 2015). TRPC1-mediated
basal influx of Ca2+ in MDA-MB-468 breast cancer cells appears to
be a trigger for the normoxic expression of HIF1α expression via a
PTEN–Akt-dependent pathway.
Mutations in the PTEN tumour supressor gene are a characteristic
of a variety of tumour types (Li et al., 1997), and in breast cancer
they are associated with metastasis and poor prognosis (Saal et al.,
2005, 2007). Loss of PTEN is awell characterised inducer of HIF1α
expression in the absence of hypoxia, via enhancement of Akt
activity (deGraffenried et al., 2004; Pore et al., 2006); however, the
potential role of Ca2+ signalling in this process has not been fully
explored. Our studies in PTEN-deficient MDA-MB-468 breast
cancer cells showed that TRPC1 silencing almost completely
abolished the expression of HIF1α under normoxic conditions, as
well as basal Akt but not basal EGFR or STAT3 phosphorylation.
The association between TRPC1 and the Akt–HIF1α axis (Pore
et al., 2006) was further supported by the inhibition of basal
HIF1α expression in MDA-MB-468 breast cancer cells with
pharmacological inhibition of Akt, the reduction in Akt
phosphorylation and HIF1α levels in HCC1569 cells with TRPC1
silencing, and the role of TRPC1 downregulation and Akt inhibition
in neurotoxin-induced ER stress in dopaminergic neurons reported
by Selvaraj et al. (2012). Given that Trpc1-null mouse phenotypes
have been described as not dramatic (Nilius and Szallasi, 2014)
and include modest body weight increases, defective saliva
secretion (Liu et al., 2007; Nilius and Szallasi, 2014) and altered
recovery from anaphylaxis (Medic et al., 2013), targeting TRPC1
Table 1. TRPC1 expression associates positively with mesenchymal ontologies and negatively with proliferation ontologies
Gene ontology term Reference Observed Expected Fold Enrichment P-value (raw)
P-value
(adjusted)
Top 100 positively associated genes by expression
Regulation of wound healing 77 5 0.42 11.87 6.26E−05 2.00E−3
Extracellular matrix organisation 211 9 1.15 7.8 2.18E−06 3.00E−04
Cellular response to growth factor stimulus 277 10 1.51 6.6 2.58E−06 3.00E−04
Ossification 282 9 1.54 5.84 2.27E−05 1.00E−03
Muscle contraction 254 8 1.39 5.76 7.29E−05 2.10E−03
Blood vessel morphogenesis 433 10 2.37 4.22 1.00E−04 2.30E−03
Coagulation 503 11 2.75 4 8.72E−05 2.30E−03
Cell migration 841 17 4.6 3.7 2.30E−06 3.00E−04
Cell adhesion 954 19 5.22 3.64 6.41E−07 2.00E−04
Organ morphogenesis 802 15 4.39 3.42 2.50E−05 1.00E−03
Regulation of cell proliferation 1177 18 6.44 2.8 5.10E−05 1.70E−03
Response to external stimulus 1323 20 7.23 2.76 2.08E−05 9.00E−04
Regulation of cellular component organisation 1214 18 6.64 2.71 7.64E−05 2.20E−03
Anatomical structure formation involved in morphogenesis 1594 22 8.72 2.52 2.99E−05 1.10E−03
Cellular developmental process 2829 30 15.47 1.94 1.00E−04 2.30E−03
Top 100 negatively associated genes by expression
Chromatin assembly 117 5 0.59 8.45 4.42E−02 4.42E−02
Nucleosome organisation 128 5 0.65 7.72 5.00E−04 4.92E−02
M phase 539 10 2.73 3.67 4.00E−04 4.72E−02
Gene ontology (GO) analysis produced a hierarchical tree of GO terms, the end point term was taken and is summarised in the table. For the full GO tree, please
see Figs S2 and S3.
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may offer a unique mechanism to regulate some of the cellular
events associated with PTEN loss in some cancers without global
systemic toxicity.
In conclusion, this study provides new insights into changes in
TRPC ion channels that are associated with hypoxia in breast cancer
cells and the role of TRPC1 in these processes. The contribution of
TRPC1 is dependent on specific oncogenic mutations such as the
tumour suppressor PTEN and the recruitment of HIF1α-dependent
and -independent pathways. This new understanding of the role of
TRPC1 in the response of breast cancer cells to hypoxia may enable
more effective targeting of cancer metastasis and/or survival
mechanisms.
MATERIALS AND METHODS
Cell culture and induction of hypoxia
MDA-MB-468 and MDA-MB-231 human breast cancer cell lines were
obtained from The Brisbane Breast Bank, UQCCR, Australia and American
Type Culture Collection (ATCC) respectively, and cultured and maintained
as previously described (Azimi et al., 2015, 2017). HCC1569 cells were
obtained from the ATCC and maintained in RPMI 1640 medium (Sigma-
Aldrich) supplemented with 10% FBS at 37°C and 5% CO2. For hypoxia
studies, 24 h post plating MDA-MB-468 breast cancer cells were serum
reduced (0.5% FBS, 24 h) and then maintained in 1% O2, 5% CO2 and
94% N2 for periods stated in results. For studies of EGF-induced EMT,
cells were serum reduced (0.5% FBS, 24 h) 24 h post plating and then
treated with 50 ng ml−1 EGF (E9644; Sigma-Aldrich) for stated periods.
Cell lines were routinely tested to confirm the absence of mycoplasma
(MycoAlert). STR profiling was performed using the StemElite ID
Profiling Kit (Promega).
Quantitative real-time PCR
Total RNAwas isolated and purified from cultured cells using an RNeasy Plus
Mini Kit (74134; Qiagen). cDNAwas synthesised using an Omniscript RTKit
(205111, Qiagen) and was amplified using TaqMan Fast Universal PCR
Master Mix (4352042; Applied Biosystems) and TaqMan gene expression
assays in a StepOnePlus instrument (Applied Biosystems) under universal
cycling conditions. The relative target quantity was determined using the
comparative CT (ΔΔCT) method by normalising to 18S rRNA as previously
described (Aung et al., 2009). The TaqMan gene expression assays used
in this study included: vimentin (Hs00185584_m1), Twist (Hs00361186_m1),
Snail (Hs00195591_m1), N-cadherin (Hs00983062_m1), claudin-4
(Hs00976831_s1), HIF-1α (Hs00153153_m1), TRPC1 (Hs00608195_m1),
TRPC3 (Hs00162985_m1), TRPC4 (Hs01077392_m1), TRPC5
(Hs00202960_m1), TRPC6 (Hs00989190_m1), TRPC7 (Hs00220638_m1),
STAT3 (Hs00374280_m1) and EGFR (Hs01076092_m1).
Immunoblotting
Cells were lysed in protein lysis buffer supplemented with protease and
phosphatase inhibitors (Roche Applied Science). Samples were resolved on
NuPAGE Novex 4-12% BisTris gels (Invitrogen) or Mini-Protean TGX
Stain-Free Precast Gels (Bio-Rad) and transferred to a PVDF membrane.
The following primary antibodies were purchased from Cell Signaling and
were diluted 1:1000: phospho-Akt (Ser473) (4051), Akt (9272), EGFR
(2232), phospho-EGFR (Tyr1173) (4407), STAT3 (9139) and phospho-
STAT3 (Tyr705). Anti-HIF-1α antibody was purchased from BD
Bioscience (610959, 1:500 dilution) and β-actin antibody was purchased
from Sigma-Aldrich (A5441, 1:10,000 dilution). HRP-conjugated
secondary antibodies goat anti-mouse (170-6516) and goat anti-rabbit
(170-6516) were purchased from Bio-Rad and used at a 1:10,000 dilution.
Primary antibodies were incubated with membrane overnight at 4°C and
secondary antibodies for 1 h at room temperature. Chemiluminescence blots
were imaged using a Bio-Rad VersaDoc Imaging System or a Bio-Rad
ChemiDoc Imaging System. Bands were quantified by Quantity One
(v.4.6.7, Bio-Rad) and normalised to β-actin. Phosphorylated proteins were
then quantified relative to their total protein. Results are expressed as
fraction of total protein band intensity.
siRNA transfection
Dharmacon ON-TARGETplus SMARTpool siRNA (100 nmol per well)
and DharmaFECT4 Transfection Reagent (0.1 µl per well) were used for
siRNA silencing (GE Dharmacon). The following ON-TARGETplus
SMARTpool siRNAs were used in this study: TRPC1 (L-004191-00),
HIF1A (L-004018-00), EGFR (L-003114-00) and STAT3 (L-003544-00).
MDA-MB-468 cells were seeded at 6×104 (48 h hypoxia) or 1×105 (6 h and
24 h hypoxia) cells per well in a 96-well plate. Post plating (24 h), cells were
transfected with siRNA for 48 h. Cells were then serum starved (0.5% FBS)
for 24 h and exposed to hypoxic conditions (1% O2) for the indicated time
periods. For experiments involving TRPC1 silencing in HCC1569 cells,
5000 cells per well were seeded in a 96-well plate and left to adhere for 24 h.
Cells were then treated with TRPC1 siRNA for 48 h and were subsequently
serum deprived (0.5% FBS). After 24 h cells in serum-deprived medium,
cells were treated with 0.1% DMSO in serum-deprived medium for 24 h,
0.5 μM acetic acid was added for 20 min, before addition of cell lysis buffer
for protein isolation
Additional experiments with different siRNAs (Dharmacon siGENOME)
are presented in Fig. S6A,B. The following Dharmacon siGENOME
siRNAs were used in this study: non-targeting (D-001206-14-05) and
TRPC1 (M-004191-02). Effectiveness of each siRNA was confirmed
through greater than 80% silencing of the relevant target gene as quantified
using real-time RT-PCR.
Akt pharmacological inhibition
For pharmacological inhibition studies, cells were seeded at 2×105 cells per
well (96-well plate) and left to adhere for 24 h before serum deprivation
(0.5% FBS) for a further 24 h. Cells were then incubated with Akt inhibitor
MK-2206 2HCl or vehicle control (0.05% DMSO) for 24 h.
Measurement of intracellular free Ca2+
Cytosolic free Ca2+ ([Ca2+]CYT) was assessed using a Fluorometric Imaging
Plate Reader (FLIPRTETRA, Molecular Devices) and the BD PBX no-wash
Ca2+ Assay Kit (BD Biosciences) as described previously (Grice et al.,
2010). Cells were seeded at 1×104 cells per well in 96-well black plates
(Corning Costar). TRPC1 and HIF1A were silenced using siRNA as
described above. Post hypoxia (24 h), cells were loaded for 60 min at 37°C
with 2 μM PBX Ca2+ indicator dye in a solution comprising 5% (v/v) PBX
Signal Enhancer and 500 μM probenecid in physiological salt solution
(PSS; 5.9 mM KCl, 1.4 mM MgCl2, 10 mM HEPES, 1.2 mM NaH2PO4,
5 mM NaHCO3, 140 mM NaCl, 11.5 mM glucose, 1.8 mM CaCl2). For
assessment of store-operated Ca2+ entry, BAPTA (500 µM, Invitrogen) was
added (for chelation of extracellular Ca2+) followed by the addition of
cyclopiazonic acid (10 µM, Sigma) [for inhibition of sarco/endoplasmic
reticulum Ca2+-ATPases (SERCA) pump and subsequent depletion of ER
Ca2+]. Store-operated Ca2+ influx was assessed by the addition of CaCl2
(0.6 mM) 700 s after the addition of cyclopiazonic acid. For the assessment
of non-stimulated Ca2+ influx, following addition of BAPTA, 0.6 mM
CaCl2 was added in the absence of cyclopiazonic acid. Fluorescence was
assessed at 470-495 nm excitation and 515-575 nm emission wavelengths.
Data analyses were performed using ScreenWorks Software (v.2.0.0.27,
Molecular Devices). Fluorescence response over baseline was assessed as a
relative measure of [Ca2+]CYT.
TRPC1 plasmid DNA transfection
TRPC1 plasmid was distributed by Addgene and was originally donated by
CraigMontell (Addgene plasmid # 24408) (Xu et al., 1997). The pcDNA3.1
vector was used for a control. MDA-MB-468 cells (4×105 cells) were
transfected with 1.2 µg plasmids in a 20 µl solution of SE Cell Line Kit
(Lonza) using DS-120 programme of a 4D-Nucleofector unit (Lonza) and
subsequently plated in 96-well plates.
Analysis of TRPC1 expression in breast cancer cell lines
For analyses of the TRPC1 gene expression profile across a panel of breast
cancer cell lines, we used a publically available microarray dataset from
Array Express (accession no. E-MTAB-181) (Heiser et al., 2012)
representing three subgroups of Luminal (predominantly luminal;
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corresponding to luminal and HER2 breast cancer subtypes), basal A
(mixed basal/luminal; corresponding to basal breast cancer subtype) and
basal B (corresponding to mesenchymal subgroup with increased invasive
properties; corresponding to claudin-low breast cancer subtype) (Neve et al.,
2006; Prat et al., 2010).
Analysis of TRPC1 expression in breast tumours
Breast tumour gene expression data were sourced from the University of
North Carolina (UNC) cohort (Harrell et al., 2012). The UNC dataset
classified its 855 tumours into the five intrinsic PAM50 molecular subtypes
and further sub-divided the basal-like and normal-like subtypes into
claudin-low tumours, basal-like (basal, 140), claudin-low (C-Low, 90),
HER2-enriched (HER2, 144), luminal A (LumA, 243), luminal B (LumB,
162) and normal-like (N-Like, 76). Triple-negative breast cancers
(TNBCs) from the UNC cohort [based on immunohistochemistry (IHC)
of the oestrogen (ER) and progesterone receptors (PR) and HER2] were
assigned a TNBC subtype based on the expression of subtype-specific
gene signatures (Burstein et al., 2015). This analysis classified the 200
TNBCs into 83 basal-like immune-activated (BLIA), 95 basal-like
immune-suppressed (BLIS), 6 luminal androgen receptor (LAR) and 16
mesenchymal (MES).
Survival analysis of basal tumours and association with TRPC1
levels
The online tool, Kaplan–Meier plotter (Györffy et al., 2010) was utilised to
produce survival curves for breast cancer patients. Two cohorts were used in
this study, all patients with basal tumours and patients with basal tumours
and classified as lymph-node positive (N+). Patient relapse-free survival
(RFS) was stratified based on TRPC1 (Affymetrix probe ID: 205802_at)
expression using the ‘Auto select best cutoff,’ feature. Patient numbers in the
low and high expression groups are displayed on the graphs, as are their
hazard ratios (HRs) and P-values.
Identification of genes most correlated to TRPC1 expression in
breast cancers
The top 100 genes positively and negatively correlated to TRPC1 expression
were sourced from TCGA microarray data (available at www.cbioportal.
org) (Cerami et al., 2012; Gao et al., 2013; Koboldt et al., 2012). This dataset
contains 463 tumours with microarray expression data. Correlations to
TRPC1 expression were calculated through both Pearson and Spearman
methodologies, Pearson was used as a cut-off for the top 100. For the
complete list of positive and negative correlated genes, please see Tables S1
and S2, respectively.
Gene ontology analysis
The top 100 genes positively and negatively correlated to TRPC1 expression
were input into the online tool WEB-based GEne SeT AnaLysis Toolkit
(WebGestalt, http://bioinfo.vanderbilt.edu/webgestalt/) (Wang et al., 2013).
Gene ontology (GO) results from this analysis were determined as
significant based on an adjusted P-value for multiple testing (Benhamini
and Hochberg method) of a hypergeometric test (raw P-value) with a
significance cut-off level of 0.05 and a minimum of 2 genes allocated to the
GO term. GO hierarchical trees produced from this analysis are available in
Figs S7 and S8, and summarised in Table 1.
TRPC1 promoter analysis
Genomic data for human mammary epithelial cell (HMEC) histone
methylation was sourced from ENCODE through the IGV browser
(Dunham et al., 2012; Robinson et al., 2011). Both Phastcons and
CpG islands were sourced from the Broad Institute data registry
(http://data.broadinstitute.org/igvdata/$$_dataServerRegistry.txt, accessed
through IGV http://software.broadinstitute.org/software/igv Version 2.3.81).
Mapped HIF1 ChIP-Seq data was sourced from GSE59937 (Zhang et al.,
2015). The HIF1 motif (RCGTGM) was sourced from Schödel et al. (2011).
Relevant data was then loaded into the Integrative genomics viewer (IGV,
Mac desktop application v.2.3.81; Robinson et al., 2011) and a snapshot
taken of human chromosome 3:142,442,229-142,445,500, build hg19.
Statistical analysis
Statistical analysis was performed using GraphPad Prism v.6.05 for
Windows (GraphPad software). Details of each test employed are
described in each figure legend. Data are presented as mean±s.d.
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